新冠特效藥概念股走強 歌禮制藥-B(1672.HK)暴漲超23%
格隆匯1月17日丨隨着奧密克戎新冠病毒繼續在全球肆虐,大量新增確診病例將使新冠特效藥需求激增,港股新冠特效藥概念股今日集體走強。其中,歌禮制藥-B(1672.HK)一度拉昇暴漲超23%報5.22港元,市值57億港元。歌禮制藥抗新冠肺炎藥物管線目前包括:已上市的利托那韋口服片劑(100mg);口服聚合酶(RdRp)抑制劑ASC10以及口服蛋白酶(3CLpro)抑制劑ASC11。1月3日,歌禮制藥曾宣佈擴大利托那韋口服片劑產能至1億片/年,利托那韋口服片劑是美國輝瑞公司已經獲批的新冠口服藥物Paxlovid的組成之一。另外,歌禮制藥計劃於2022年上半年向中國、美國等國家提交ASC10臨牀試驗申請;計劃於2022年下半年向中國、美國等國家提交ASC11臨牀試驗申請。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.